Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2025)

Perspective Therapeutics (CATX) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $26.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.6 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $26.6 million for FY2025, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue hit $26.6 million in Q4 2025 for Perspective Therapeutics, roughly flat from $26.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $26.6 million in Q1 2024 to a low of $26.6 million in Q1 2024.